Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:21:00 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:SMMT - SUMMIT THERAPEUTICS INC - https://www.summitplc.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SMMT - Q0.13.34·3.921.13.86+0.318.71,388.94,9464,9173.63  3.90  3.525.22  1.3018:08:37Apr 2415 min RT 2¢

Recent Trades - Last 10 of 4917
Time ETExPriceChangeVolume
18:08:37Q3.860.31250
18:06:10Q3.860.31229
17:35:59Q3.860.3110
17:30:32Q3.860.31161
16:37:33Q3.860.3120
16:20:00Q3.860.31858
16:13:44Q3.860.3142
16:02:05Q3.860.31257
16:01:44Q3.860.31106
16:01:41Q3.860.312,761

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-24 16:30U:SMMTNews ReleaseSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
2024-04-11 16:30U:SMMTNews ReleaseSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
2024-04-10 07:00U:SMMTNews ReleaseSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
2024-03-22 07:00U:SMMTNews ReleasePromising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
2024-03-14 07:00U:SMMTNews ReleaseIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
2024-03-05 07:00U:SMMTNews ReleaseSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
2024-02-20 07:00U:SMMTNews ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
2024-02-14 07:00U:SMMTNews ReleaseSummit Therapeutics to Host Fourth Quarter & Full Year 2023
2024-02-07 07:00U:SMMTNews ReleaseSummit Therapeutics to Present at Oppenheimer ¢ € ™s 34th Annual Healthcare Life Sciences Conference
2024-01-08 09:00U:SMMTNews ReleaseSummit Therapeutics Announces Updated Phase II Data for Ivonescimab at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-03 07:30U:SMMTNews ReleaseSummit Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-07 07:00U:SMMTNews ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
2023-11-02 16:41U:SMMTNews ReleaseLaura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development
2023-10-31 08:00U:SMMTNews ReleaseIvonescimab ¢ € ™s Novel Mechanism of Action Highlighting Cooperative Binding to be Featured in Poster Presentation at SITC 2023
2023-10-26 08:00U:SMMTNews ReleaseSummit Therapeutics to Host Q3 2023 Financial Results & Operational Progress Call on November 7, 2023
2023-10-19 08:00U:SMMTNews ReleaseH. Jack West, MD, Renowned Oncologist & Lung Cancer Expert, Joins Summit Therapeutics as Vice President of Clinical Development
2023-10-16 07:00U:SMMTNews ReleaseSummit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer
2023-08-09 07:00U:SMMTNews ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023
2023-08-02 08:00U:SMMTNews ReleaseSummit Therapeutics to Host Q2 2023 Financial Results & Operational Progress Call on August 9, 2023
2023-06-04 08:00U:SMMTNews ReleasePromising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023